VEL 0230 | 221144-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 中文名称: VEL 0230
• 英文名称: VEL-0230
• 英文别名: sodium (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]-oxirane-2-carboxylate；sodium;(2S,3S)-3-carboxy-N-[(2S)-4-methyl-1-(2-methylpropoxy)pentan-2-yl]oxirane-2-carboximidate
• CAS: 221144-20-3
• 化学式: C₁₄H₂₄NO₅*Na
• 分子量: 309.338
• InChiKey: SGAKODIXAHVUKL-LFELFHSZSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.29
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  91
• 氢给体数：
  1
• 氢受体数：
  5

制备方法与用途

VEL-0230（NC-2300）是一种强效且选择性的半胱氨酸天冬酶抑制剂，其对Cat B、K和S的IC50值分别为284纳摩尔、34.5纳摩尔和186纳摩尔。

反应信息

• 作为产物：
  描述：

  ethyl (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylate 在 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以70.3%的产率得到VEL 0230
  参考文献：
  名称：

  SALTS OF (2S,3S)-3- [[(1S)-1-ISOBUTOXYMETHYL-3-METHYLBUTYL]CARBAMOYL] OXIRANE-2-CARBOXYLIC ACID

  摘要：

  公开号：

  EP1619190B1

文献信息

• Epoxysuccinamide derivatives
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US06689785B2

  公开（公告）日：2004-02-10

  Novel epoxysuccinamide derivatives represented by the general formula (1) or physiologically acceptable salts thereof, which are useful particularly as remedies for bone diseases and arthritis, wherein R1 and R3 are each hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or a heterocyclic-alkyl group; R2 is alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or a hetericyclic-alkyl group; X is —O— or —NR4— (wherein R4 is hydrogen, alkyl, aryl, aralkyl, a heterocyclic group, or a heterocyclic-alkyl group; Y1 is OR5, SR6, or NR7R8 (wherein each of R5, R6 and R7 is hydrogen, alkyl, aryl, aralkyl, acyl, a heterocyclic group, or a heterocyclic-alkyl group, and R8 is the same as defined for R4); and Y2 is hydrogen or alkyl, or alternatively Y1 and Y2 can be combined to form ═O, ═S, ═N—R9, or ═N—OR10 (wherein each of R9 and R10 is the same as defined for R4), provided that each of the alkyl, aryl and heterocyclic groups defined for R5 to R10 can have one or more specific substituents and that each of the group defined for R1 to R10 and Y2 is specificed in the number of carbon atoms.

  一般式（1）或其生理上可接受的盐所代表的新型环氧琥珀酰胺衍生物，特别适用于治疗骨疾病和关节炎，其中R1和R3分别为氢、烷基、烯基、炔基、芳基、芳基烷基、杂环基或杂环基烷基；R2为烷基、烯基、炔基、芳基、芳基烷基、杂环基或杂环基烷基；X为—O—或—NR4—（其中R4为氢、烷基、芳基、芳基烷基、杂环基或杂环基烷基；Y1为OR5、SR6或NR7R8（其中R5、R6和R7中的每一个为氢、烷基、芳基、芳基烷基、酰基、杂环基或杂环基烷基，而R8与R4的定义相同）；Y2为氢或烷基，或者Y1和Y2可以结合形成═O、═S、═N—R9或═N—OR10（其中R9和R10中的每一个与R4的定义相同），前提是为R5到R10定义的烷基、芳基和杂环基可以有一个或多个特定的取代基，而为R1到R10和Y2定义的每一个基团都具有特定的碳原子数。
• Salt of (2s, 3s) -3- [ [ (is) -1- isobutoxymethyl-3-methylbutyl] carbamoly] oxirane-2-carboxylic acid
  申请人：Tendo Atsushi

  公开号：US20060252826A1

  公开（公告）日：2006-11-09

  The invention relates to purification of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid [hereinafter, referred to as the carboxylic acid] using the salt of the carboxylic acid with an organic amine selected from the group consisting of piperazine, adamantane amines and others. The invention also relates to providing crystalline sodium salt of the carboxylic acid. The sodium salt is usable as a material for preparing medicaments and improved in storage stability, and has the following characteristics: DSC: exothermic peak observed at a temperature in the range of 170 to 175° C. with weight decrease; and characteristic absorption bands of infrared absorption spectrum (KBr tablet): 3255, 2950, 2860, 1670, 1630, 1550, 1460, 1435, 1395, 1365, 1310, 1260, 1110, 890 cm −1 .

  本发明涉及使用来自于由哌嗪、金刚烷胺和其他有机胺组成的组中所选的有机胺与羧酸盐一起进行纯化，来纯化(2S,3S)-3-[[(1S)-1-异丁氧甲基-3-甲基丁基]氨基甲酰]环氧丙烷-2-羧酸（以下简称羧酸）。本发明还涉及提供羧酸的结晶钠盐。该钠盐可用作制备药物的材料，并且在储存稳定性方面得到改善，具有以下特征：DSC：在170至175℃范围内观察到一个放热峰和重量下降；并且具有红外吸收光谱（KBr片）的特征吸收带：3255、2950、2860、1670、1630、1550、1460、1435、1395、1365、1310、1260、1110、890 cm-1。
• SALT OF (2S, 3S)-3-[[ (1S)-1-ISOBUTOXYMETHYL-3-METHYLBUTYL] CARBAMOYL] OXIRANE-2-CARBOXYLIC ACID
  申请人：TENDO Atsushi

  公开号：US20090312563A1

  公开（公告）日：2009-12-17

  The invention relates to purification of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid [hereinafter, referred to as the carboxylic acid] using the salt of the carboxylic acid with an organic amine selected from the group consisting of piperazine, adamantane amines and others. The invention also relates to providing crystalline sodium salt of the carboxylic acid. The sodium salt is usable as a material for preparing medicaments and improved in storage stability, and has the following characteristics: DSC: exothermic peak observed at a temperature in the range of 170 to 175° C. with weight decrease; and characteristic absorption bands of infrared absorption spectrum (KBr tablet) 3255, 2950, 2860, 1670, 1630, 1550, 1460, 1435, 1395, 1365, 1310, 1260, 1110, 890 cm −1 .

  本发明涉及使用来自于由吡啶、金刚烷胺和其他有机胺中选择的有机胺盐对(2S,3S)-3-[[(1S)-1-异丁氧甲基-3-甲基丁基]氨基甲酰]环氧丙烷-2-羧酸（以下简称羧酸）进行纯化的方法。本发明还涉及提供羧酸的结晶钠盐。钠盐可用作制备药物的材料，并且具有以下特点：DSC：在170至175℃的温度范围内观察到放热峰，伴随重量减少；以及红外吸收光谱（KBr片）的特征吸收带3255、2950、2860、1670、1630、1550、1460、1435、1395、1365、1310、1260、1110、890 cm-1。
• Salt of (2S, 3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid
  申请人：Velcura Therapeutics, Inc.

  公开号：US08163942B2

  公开（公告）日：2012-04-24

  The invention relates to purification of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid [hereinafter, referred to as the carboxylic acid] using the salt of the carboxylic acid with an organic amine selected from the group consisting of piperazine, adamantane amines and others. The invention also relates to providing crystalline sodium salt of the carboxylic acid. The sodium salt is usable as a material for preparing medicaments and improved in storage stability, and has the following characteristics: DSC: exothermic peak observed at a temperature in the range of 170 to 175° C. with weight decrease; and characteristic absorption bands of infrared absorption spectrum (KBr tablet): 3255, 2950, 2860, 1670, 1630, 1550, 1460, 1435, 1395, 1365, 1310, 1260, 1110, 890 cm−1.

  本发明涉及使用来自于吡啶、金刚烷胺和其他有机胺组成的群体中所选的有机胺与该羧酸的盐来纯化(2S,3S)-3-[[(1S)-1-异丁氧甲基-3-甲基丁基]氨基甲酰]环氧丙烷-2-羧酸[以下简称为羧酸]。本发明还涉及提供羧酸的晶体钠盐。该钠盐可用作制备药物的材料，并具有良好的储存稳定性，具有以下特征：DSC：在170至175℃范围内观察到放热峰，并伴随重量下降；红外吸收光谱的特征吸收带(KBr片)：3255、2950、2860、1670、1630、1550、1460、1435、1395、1365、1310、1260、1110、890 cm-1。
• Salt of (2S, 3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl] carbamoyl] oxirane-2-carboxylic acid
  申请人：Nippon Chemiphar Co., Ltd

  公开号：US07795458B2

  公开（公告）日：2010-09-14

  The invention relates to purification of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid [hereinafter, referred to as the carboxylic acid] using the salt of the carboxylic acid with an organic amine selected from the group consisting of piperazine, adamantane amines and others. The invention also relates to providing crystalline sodium salt of the carboxylic acid. The sodium salt is usable as a material for preparing medicaments and improved in storage stability, and has the following characteristics: DSC: exothermic peak observed at a temperature in the range of 170 to 175° C. with weight decrease; and characteristic absorption bands of infrared absorption spectrum (KBr tablet) 3255, 2950, 2860, 1670, 1630, 1550, 1460, 1435, 1395, 1365, 1310, 1260, 1110, 890 cm−1.

  本发明涉及使用来自于吡啶、金刚烷胺和其他有机胺的盐对(2S,3S)-3-[[(1S)-1-异丁氧甲基-3-甲基丁基]氨基甲酰基]环氧丙烷-2-羧酸[以下简称羧酸]进行纯化的方法。本发明还涉及提供羧酸的晶体钠盐。该钠盐可用作制备药物的材料，并具有改善的储存稳定性，具有以下特征：DSC：在170至175°C范围内观察到放热峰并伴随重量下降；以及红外吸收光谱(KBr片)的特征吸收带3255、2950、2860、1670、1630、1550、1460、1435、1395、1365、1310、1260、1110、890 cm-1。